<table>
<thead>
<tr>
<th>Date</th>
<th>Time PDT</th>
<th>Track</th>
<th>Presentation Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>30-Sep</td>
<td>6:00-7:00 AM</td>
<td>Industry Speaker</td>
<td>Comparative genome and transcriptome analysis of small cell numbers</td>
<td>Christian Korfhage, PhD Director, Scientific Applications: NGS &amp; Isothermal Amplifications, QIAGEN</td>
</tr>
<tr>
<td>30-Sep</td>
<td>6:00-7:00 AM</td>
<td>Prostate Cancer Mini-symposium</td>
<td>Keynote Presentation: What's New and in the News with Prostate Cancer 2015</td>
<td>Judd W Moul, MD, FACS James H Semans MD Professor of Surgery, Division of Urologic Surgery, Director, Duke Prostate Center, Duke Cancer Institute, Duke University Medical Center</td>
</tr>
<tr>
<td>30-Sep</td>
<td>7:30-8:30 AM</td>
<td>Prostate Cancer Mini-symposium</td>
<td>How do I choose? Androgen Biosynthesis Inhibitor, Androgen Receptor Antagonist, or both for treatment of mCRPC?</td>
<td>Lawrence Karsh MD FACS Director of Research, CPI &amp; Attending Urologist, The Urology Center of Colorado</td>
</tr>
<tr>
<td>30-Sep</td>
<td>7:30-8:30 AM</td>
<td>Innovations in Cancer Immunotherapy</td>
<td>Humanized NSGTM Mice for Evaluation of Immuno-Oncology Therapeutics</td>
<td>Brian Soper, PhD Technical Information Scientist, The Jackson Laboratory</td>
</tr>
<tr>
<td>30-Sep</td>
<td>7:30-8:30 AM</td>
<td>Targeted, precision therapies for advanced disease</td>
<td>Ligand-Targeted Therapies for Cancer and Autoimmune Diseases</td>
<td>Philip S. Low, PhD Director of the Purdue Center for Drug Discovery Ralph C. Corley Distinguished Professor Department of Chemistry, Purdue University</td>
</tr>
<tr>
<td>30-Sep</td>
<td>9:00-10:00 AM</td>
<td>Prostate Cancer Mini-symposium</td>
<td>Inventing Active Surveillance version 2.0</td>
<td>Eric Klein, MD Chairman of the Glickman Urological &amp; Kidney Institute, Cleveland Clinic</td>
</tr>
<tr>
<td>30-Sep</td>
<td>9:00-10:00 AM</td>
<td>Cancer Metabolism</td>
<td>Lactate-driven metabolic adaptation modulates breast cancer progression</td>
<td>Jennifer Molina, PhD Institute Research Scientist, Institute for Applied Cancer Science at MD Anderson Cancer Center</td>
</tr>
<tr>
<td>30-Sep</td>
<td>10:30-11:30 AM</td>
<td>Prostate Cancer Mini-Symposium</td>
<td>The Evolving Role of Image-Guided Prostate Cancer Targeting and Ablation: Moving Towards Personalized Medicine</td>
<td>Rajan Gupta, MD Assistant Professor of Radiology, Director, Abdominal Imaging Fellowship Program, Duke University School of Medicine Thomas Polascik, MD Professor of Surgery, Director, Society of Urologic Oncology Program, Director, Genitourinary Program on Focal Therapy, Duke Cancer Institute, Duke University Medical Center Stacy Loeb, MD Assistant Professor of Urology and Population Health, NYU School of Medicine</td>
</tr>
<tr>
<td>Date</td>
<td>Time</td>
<td>Event Title</td>
<td>Session Title</td>
<td>Speaker(s)</td>
</tr>
<tr>
<td>------</td>
<td>-------</td>
<td>------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 30-Sep | 12:00-1:00 PM | Prostate Cancer Mini-symposium | Keynote Presentation: What's New in Robotics and minimally invasive therapy for prostate cancer and prostate disease | David Albala, MD  
Chief of Urology at Crouse Hospital and Medical Director for Associated Medical Professionals  
Herbert Lepor, MD  
Urologist, NYU Langone Medical Center |
| 30-Sep | 12:00-1:00 PM | Innovations in cancer immunotherapy | Modeling and dissecting hepatocellular carcinoma dissemination | Brian Lewis, PhD  
Associate Professor, Molecular, Cell and Cancer Biology, University of Massachusetts Medical School |
| 30-Sep | 1:30-2:30 PM | Targeted, precision therapies for advanced disease | Biomarkers: An Auspicious Beginning and a Portentous Future? | Anna Barker, PhD  
Co-Director, Complex Adaptive Systems Initiative, Director, Transformative Healthcare Networks, Professor, School of Life Sciences, Arizona State University (ASU) |
| 30-Sep | 1:30-2:30 PM | Industry Speaker | Role of microRNA-mRNA interactions in Endometrioid Endometrial Carcinoma, a "Sample to Insight" biological exploration | Jean-Noel Billaud, PhD  
Principal Scientist, QIAGEN Bioinformatics |
| 30-Sep | 1:30-2:30 PM | Progress in detection of rare cancer mutations and Implications for treatment | SuperSelective Primers for the Multiplex Quantitation of Rare Mutant Sequences Associated with Cancer | Fred Kramer, PhD  
Professor, Public Health Research Institute, New Jersey Medical School, Rutgers University |
| 1-Oct | 6:00-7:00 AM | The "Liquid Biopsy" : applications for blood-based noninvasive cancer diagnostics | Emerging role of liquid biopsies and NGS for biomarker discovery | Raed Samara, PhD  
Senior Global Product Manager, QIAGEN |
| 1-Oct | 7:30-8:30 AM | Melanoma Mini-Symposium | A Case Study for Immunotherapies and Targeted Therapies | Louise Perkins, PhD  
Chief Science Officer, Melanoma Research Alliance |
| 1-Oct | 7:30-8:30 AM | Targeted, precision therapies for advanced disease | Latest clinical results in oncology drug management | Salvatore J Salamone, PhD  
Founder and Chief Scientific Officer, Saladax Biomedical, Inc. |
| 1-Oct | 9:00-10:00 AM | Melanoma Mini-Symposium | Engaging the Patient in the Treatment Journey | Timothy Turnham, PhD  
Executive Director, Melanoma Research Foundation  
Shelby Moneer, MS, CHES  
Director of Education, Melanoma Research Foundation |
| 1-Oct | 9:00-10:00 AM | Progress in detection of rare cancer mutations and Implications for treatment | RNA-editing in melanoma - Case for a sensitive analysis and interpretation platform for the resolution of a diverse molecular process and likely pathogenic variants | Anika Joecker, PhD  
Associate Director Global Product Management NGS, QIAGEN |
<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
</table>
| 1-Oct | 10:30-11:30 AM | Melanoma Mini-Symposium         | How the diagnosis of melanoma is made: clinical detection/recognition and histologic/genetic assessment | Whitney High, MD, JD, M.Eng  
Director of Dermatopathology (Dermatology), Associate Professor, Dermatology & Pathology, University of Colorado School of Medicine |
Marketing Director at Immunochemistry Technologies, LLC |
| 1-Oct | 12:00-1:00 PM   | Tools and Strategies for Improving Clinical trial outcomes and Predictive modeling | Can the World's First Animal Study Software to Emulate Clinical Trial Approaches Improve Clinical Outcome Predictability? | Eric Ibsen  
Vice President, Studylog Systems |
| 1-Oct | 12:00-1:00 PM   | Progress in detection of rare cancer mutations and Implications for treatment | Detection and sequencing of rare mutations using mutation enrichment via COLD-PCR | Mike Makrigiorgos, PhD, DABMP  
Professor and Director, Division of Medical Physics and Biophysics, Director, DNA technology and SARRP pre-clinical laboratories, Brigham and Women's Hospital, Dana-Farber Cancer Institute |
| 1-Oct | 1:30-2:30 PM    | Melanoma Mini-Symposium         | Keynote Presentation (during an actual infusion!): Patient #1 - Pioneering Immunotherapy and Finding The Best, Right Treatment for Stage IV Melanoma | T.J. Sharpe  
Patient, Survivor, Advocate, and Author of the "Patient #1" blog |
| 1-Oct | 1:30-2:30 PM    | Targeted, precision therapies for advanced disease | Data, Data, Everywhere - Using Complexity Analysis to find coherence in Cancer Big Data | Kenneth Buetow, PhD, FACMI  
Director of Computational Sciences and Informatics program for Complex Adaptive Systems and Professor in the School of Life Sciences, Arizona State University |